-+ 0.00%
-+ 0.00%
-+ 0.00%

Kodiak Sciences Q2 FY26 net loss widens to $65.64 million

PUBT·08/13/2026 20:00:40
Listen to the news
Kodiak Sciences Q2 FY26 net loss widens to $65.64 million
  • Kodiak Sciences posted a GAAP net loss of USD 65.6 million, or USD 1.05 a share, for the second quarter ended June 30, 2026.
  • R&D expense climbed 31% year over year to USD 56.1 million, on higher PEAK/PINNACLE clinical activity and Phase 3 manufacturing.
  • Cash and cash equivalents fell to USD 125.9 million at quarter-end; operations are expected to be funded into 2027.
  • Phase 3 DAYBREAK topline results for Zenkuda and KSI-501 in treatment-naïve wet AMD are expected in September 2026.
  • Phase 3 PEAK Pivotal Analysis 1 topline results for KSI-101 in MESI are expected in December 2026; Phase 3 ALTO in DME has begun enrolling.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kodiak Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608131600PR_NEWS_USPR_____SF26244) on August 13, 2026, and is solely responsible for the information contained therein.